Table 1.
Characteristics of cohorts.
| Non-DMT-exposed (n = 216) | IFNβ (n = 78) | GA exposed (n = 41) | p-value | |
|---|---|---|---|---|
| Age, mean (SD) in years | 31.01 (± 4.57) | 31.03 (± 4.05) | 31.29 (± 3.42) | |
| Disease duration, median (range) in years | 4.95 (± 3.74) | 5.38 (± 3.87) | 6.58 (± 3.93) | |
| RR prior 1 year, mean (SD) | 0.9 (± 1.8) | 1.04 (± 0.75) | 0.68 (± 4.7) | |
| RR during pregnancy mean (SD), p-values (as compared with prepregnancy RR) | ||||
| 1. Trimester | 0.37 (± 1.2) | 0.38 (± 1.2) | 0.2 (± 0.8) | |
| p < 0.0001 | p < 0.0001 | p = 0.002 | ||
| 2. Trimester | 0.26 (± 1) | 0.1 (± 0.7) | 0.3 (± 1.1) | |
| p < 0.0001 | p < 0.0001 | p < 0.0001 | ||
| 3. Trimester | 0.15 (± 8.8) | 0.38 (± 1.2) | 0.1 (± 0.6) | |
| p < 0.0001 | p < 0.0001 | p = 0.01 | ||
| RR postpartum mean (SD), p-values (as compared with last trimester pregnancy RR, respectively) | 1.3 (± 1.9) | 0.8 (± 1.6) | 0.6 (± 1.4) | |
| p < 0.0001 | p < 0.0001 | p < 0.02 | ||
| EBF n (%) | 113 (53) | 37 (49) | 20 (51) | ns/ns |
| MS treatment | 20 (9.3) | 30 (38.5) | 16 (39) | p < 0.001 |
| IVIG n (%) postpartum | p < 0.001 | |||
| DMT (IFNβ, GA) Within 1 month postpartum | 41 (19) | 25 (32.05) | 6 (10) | p < 0.001 |
| ns |
DMT, disease-modifying therapy; IVIG, intravenous immunoglobulin; MS, multiple sclerosis; IFN, interferon; GA, glatiramer acetate; RR, relapse rate; EBF, exclusively breastfed.
Data are given as mean ± SD, respectively as total number.
***
p < 0.001 of the analysis of variance (ANOVA) between the three cohorts; age, duration and total time is given in years.
Last column: first p-value: non-DMT exposed compared with IFN; second p-value: non-DMT-exposed compared with GA.